TY - JOUR
T1 - GD2 expression in breast cancer
AU - Orsi, Giulia
AU - Barbolini, Monica
AU - Ficarra, Guido
AU - Tazzioli, Giovanni
AU - Manni, Paola
AU - Petrachi, Tiziana
AU - Mastrolia, Ilenia
AU - Orvieto, Enrico
AU - Spano, Carlotta
AU - Prapa, Malvina
AU - Kaleci, Shaniko
AU - D'Amico, Roberto
AU - Guarneri, Valentina
AU - Dieci, Maria Vittoria
AU - Cascinu, Stefano
AU - Conte, Pierfranco
AU - Piacentini, Federico
AU - Dominici, Massimo
PY - 2017/3/18
Y1 - 2017/3/18
N2 - Breast cancer (BC) is a heterogeneous disease, including different subtypes having diverse incidence, drug-sensitivity and survival rates. In particular, claudinlow and basal-like BC have mesenchymal features with a dismal prognosis. Disialoganglioside GD2 is a typical neuroectodermal antigen expressed in a variety of cancers. Despite its potential relevance in cancer diagnostics and therapeutics, the presence and role of GD2 require further investigation, especially in BC. Therefore, we evaluated GD2 expression in a cohort of BC patients and its correlation with clinicalpathological features. Sixty-three patients with BC who underwent surgery without prior chemo- and/or radiotherapy between 2001 and 2014 were considered. Cancer specimens were analyzed by immunohistochemistry and GD2-staining was expressed according to the percentage of positive cells and by a semi-quantitative scoring system. Patient characteristics were heterogeneous by age at diagnosis, histotype, grading, tumor size, Ki-67 and receptor-status. GD2 staining revealed positive cancer cells in 59% of patients. Among them, 26 cases (41%) were labeled with score 1+ and 11 (18%) with score 2+. Notably, the majority of metaplastic carcinoma specimens stained positive for GD2. The univariate regression logistic analysis revealed a significant association of GD2 with triple-receptor negative phenotype and older age (> 78) at diagnosis. We demonstrate for the first time that GD2 is highly prevalent in a cohort of BC patients clustering on very aggressive BC subtypes, such as triple-negative and metaplastic variants.
AB - Breast cancer (BC) is a heterogeneous disease, including different subtypes having diverse incidence, drug-sensitivity and survival rates. In particular, claudinlow and basal-like BC have mesenchymal features with a dismal prognosis. Disialoganglioside GD2 is a typical neuroectodermal antigen expressed in a variety of cancers. Despite its potential relevance in cancer diagnostics and therapeutics, the presence and role of GD2 require further investigation, especially in BC. Therefore, we evaluated GD2 expression in a cohort of BC patients and its correlation with clinicalpathological features. Sixty-three patients with BC who underwent surgery without prior chemo- and/or radiotherapy between 2001 and 2014 were considered. Cancer specimens were analyzed by immunohistochemistry and GD2-staining was expressed according to the percentage of positive cells and by a semi-quantitative scoring system. Patient characteristics were heterogeneous by age at diagnosis, histotype, grading, tumor size, Ki-67 and receptor-status. GD2 staining revealed positive cancer cells in 59% of patients. Among them, 26 cases (41%) were labeled with score 1+ and 11 (18%) with score 2+. Notably, the majority of metaplastic carcinoma specimens stained positive for GD2. The univariate regression logistic analysis revealed a significant association of GD2 with triple-receptor negative phenotype and older age (> 78) at diagnosis. We demonstrate for the first time that GD2 is highly prevalent in a cohort of BC patients clustering on very aggressive BC subtypes, such as triple-negative and metaplastic variants.
KW - BC
KW - Disialoganglioside
KW - GD2
KW - Metaplastic
KW - TNBC
UR - http://www.scopus.com/inward/record.url?scp=85019096580&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019096580&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.16363
DO - 10.18632/oncotarget.16363
M3 - Article
AN - SCOPUS:85019096580
VL - 8
SP - 31592
EP - 31600
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 19
ER -